)
Visual
test
Idorsia
Idorsia (IDIA) investor relations material
Idorsia 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic overview and leadership
New CEO presented a focused strategy to commercialize two key assets and advance a robust pipeline, leveraging legacy expertise from Actelion.
Emphasis on disciplined execution and value creation for both patients and shareholders, with forward-looking statements for 2026.
Focus on two products with blockbuster potential and a robust pipeline of first- or best-in-class drugs.
Strategic alliances and global partnerships drive expansion and access to new markets.
Financially positioned for growth with a cash runway into 2028 and on-track to deliver 2025 guidance.
Product highlights and market opportunities
QUVIVIQ (daridorexant) is the only therapy to show improvement in daytime functioning for insomnia, with global label inclusion except in the U.S.
Rapid global expansion of QUVIVIQ, with approvals and launches in the US, EU, Japan, China, and other regions; over 100,000 patients in China post-launch.
TRYVIO (aprocitentan) is the first dual ERA approved for systemic hypertension, targeting a multi-billion dollar market and addressing a major public health issue with 1.4 billion global patients.
TRYVIO demonstrates strong efficacy and safety, with positive feedback from top hypertension centers and a path to $5B peak sales.
Both products are entering a value-acceleration phase, with clear paths to blockbuster scale.
Pipeline and innovation
Two late-stage assets with Viatris: selatogrel (acute MI) and cenerimod (systemic lupus), both in Phase III with milestone/royalty structure.
Lucerostat for Fabry disease offers a mutation-independent oral alternative, with promising secondary endpoints and upcoming data, targeting a $4B market.
Early-stage pipeline includes chemokine receptor antagonists for psoriasis, progressive MS, and vitiligo, with new trials starting in 2026.
Synthetic glycan vaccine platform targets C. difficile and other MDR bacteria, with proof-of-concept and dose-dependent immunogenicity.
Multiple assets are designed for multi-billion dollar peak sales potential.
Impact of QUVIVIQ US label expansion on payers
TRYVIO's strategy for add-on vs. switch patients
Future applications of synthetic glycan platform
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance.
Next Idorsia earnings date
Q4 202526 Feb, 2026
Idorsia
Next Idorsia earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Idorsia Ltd is a biopharmaceutical company based in Switzerland, specializing in the discovery, development, and commercialization of small molecules. The company targets a wide range of diseases, including Fabry disease, insomnia, resistant hypertension, cerebral vasospasm, epilepsy, nasal polyposis, and systemic lupus erythematosus, among others. Idorsia's approach spans multiple therapeutic areas such as CNS, cardiovascular, and immunological disorders, as well as orphan diseases. The company is headquartered in Allschwil, near Basel, Switzerland, and its shares are listed on the SIX Swiss Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage